LOTUS HEALTH GROUP COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.13 CNY | -1.43% |
|
-5.28% | -31.74% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,007 | 2,942 | 3,891 | 5,400 | 4,824 | 10,736 |
| Enterprise Value (EV) 1 | 2,647 | 2,250 | 3,788 | 4,209 | 3,479 | 9,576 |
| P/E ratio | -6.1 x | 42.6 x | 56.4 x | 100 x | 90.3 x | 86.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.16 x | 1.73 x | 2.35 x | 2.98 x | 2.85 x | 5.11 x |
| EV / Revenue | 1.53 x | 1.32 x | 2.29 x | 2.32 x | 2.06 x | 4.56 x |
| EV / EBITDA | -15.8 x | -12.1 x | 30.4 x | 54.7 x | 39.6 x | 47.5 x |
| EV / FCF | 57.7 x | 16.6 x | -6.09 x | 45.3 x | 25 x | -44.6 x |
| FCF Yield | 1.73% | 6.02% | -16.4% | 2.21% | 4.01% | -2.24% |
| Price to Book | -6.73 x | 9.46 x | 10.1 x | 3.84 x | 3.41 x | 8.02 x |
| Nbr of stocks (in thousands) | 13,79,933 | 13,79,933 | 13,79,924 | 17,93,901 | 17,80,185 | 17,74,520 |
| Reference price 2 | 1.455 | 2.132 | 2.820 | 3.010 | 2.710 | 6.050 |
| Announcement Date | 26/04/19 | 30/03/20 | 30/03/21 | 29/04/22 | 30/03/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,729 | 1,703 | 1,655 | 1,815 | 1,691 | 2,101 |
| EBITDA 1 | -167.1 | -185.2 | 124.6 | 76.94 | 87.91 | 201.6 |
| EBIT 1 | -206.1 | -210.9 | 113.2 | 65.6 | 70.41 | 184.5 |
| Operating Margin | -11.92% | -12.39% | 6.84% | 3.61% | 4.16% | 8.78% |
| Earnings before Tax (EBT) 1 | -389.7 | 50.87 | 104.1 | 53.7 | 60.39 | 170.8 |
| Net income 1 | -332.5 | 69.23 | 74.29 | 44.36 | 46.17 | 129.9 |
| Net margin | -19.23% | 4.07% | 4.49% | 2.44% | 2.73% | 6.18% |
| EPS 2 | -0.2386 | 0.0500 | 0.0500 | 0.0300 | 0.0300 | 0.0700 |
| Free Cash Flow 1 | 45.84 | 135.4 | -622.4 | 92.89 | 139.4 | -214.6 |
| FCF margin | 2.65% | 7.95% | -37.62% | 5.12% | 8.24% | -10.22% |
| FCF Conversion (EBITDA) | - | - | - | 120.73% | 158.55% | - |
| FCF Conversion (Net income) | - | 195.6% | - | 209.39% | 301.88% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 26/04/19 | 30/03/20 | 30/03/21 | 29/04/22 | 30/03/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 640 | - | - | - | - | - |
| Net Cash position 1 | - | 692 | 103 | 1,191 | 1,345 | 1,160 |
| Leverage (Debt/EBITDA) | -3.828 x | - | - | - | - | - |
| Free Cash Flow 1 | 45.8 | 135 | -622 | 92.9 | 139 | -215 |
| ROE (net income / shareholders' equity) | 127% | -13.3% | 68.5% | 6.5% | 4% | 10.4% |
| ROA (Net income/ Total Assets) | -7.16% | -6.83% | 3.87% | 2.18% | 1.88% | 4.74% |
| Assets 1 | 4,644 | -1,014 | 1,920 | 2,038 | 2,461 | 2,739 |
| Book Value Per Share 2 | -0.2200 | 0.2300 | 0.2800 | 0.7800 | 0.7900 | 0.7500 |
| Cash Flow per Share 2 | 0.0300 | 0.8800 | 0.3400 | 0.6700 | 0.7800 | 0.6100 |
| Capex 1 | 5.11 | 1.22 | 90.2 | 102 | 41.6 | 110 |
| Capex / Sales | 0.3% | 0.07% | 5.45% | 5.59% | 2.46% | 5.24% |
| Announcement Date | 26/04/19 | 30/03/20 | 30/03/21 | 29/04/22 | 30/03/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -31.74% | 102.8Cr | |
| -0.13% | 2.94TCr | |
| +19.19% | 2.47TCr | |
| +3.83% | 1.11TCr | |
| +16.23% | 534.96Cr | |
| +18.12% | 454Cr | |
| -6.77% | 395.51Cr | |
| +0.04% | 301.68Cr | |
| +24.77% | 281.88Cr | |
| -7.77% | 258.96Cr |
- Stock Market
- Equities
- 600186 Stock
- Financials Lotus Health Group Company